NY-EDELMAN
25.7.2022 13:07:11 CEST | Business Wire | Press release
Edelman today announced the global launch of Edelman Smithfield, a financial communications boutique that specializes in the financial markets and strategic situations, serving clients in the United States, EMEA, Asia and beyond. The global launch brings together under one brand Edelman’s Financial Communications and Financial Services teams, combining specialized industry knowledge with global scale and localized expertise, while remaining connected to and integrated with Edelman’s full capabilities. Lex Suvanto will serve as Edelman Smithfield Global CEO.
Edelman Smithfield is focused on advising senior leaders and management teams navigating complex matters that impact reputation and valuation. The firm has deep expertise serving and communicating to the financial markets and is comprised of two primary practice areas:
- Partnering with companies in the financial markets to help them protect, promote and evolve their reputation. Edelman Smithfield is a leading communications advisor in the financial markets, working with investment firms, private equity and venture capital funds, hedge funds, banks, insurers, fintech, crypto and other financial markets participants to develop and execute tailored communications programs that build trust and strengthen reputations in the marketplace.
- Partnering with companies navigating and communicating with the financial markets and during strategic situations. Edelman Smithfield advises boards of directors, management teams and communications professionals on high impact strategic situations, such as mergers, acquisitions, IPOs, bankruptcies and restructurings, shareholder activism, litigation, management changes and regulatory matters, as well as ongoing engagement with the investment community, including investor relations and critical ESG matters.
Richard Edelman, CEO of Edelman, said, “The financial communications team has built an incredible platform and has advised on some of the highest profile clients and situations over the past several years. We continue to see significant demand from both existing and new clients for the work that they are leading, especially given the volatility and complexity of the global financial markets. There’s tremendous opportunity ahead, and we will continue to invest in Edelman Smithfield to ensure the team is well placed to define the next generation of financial communications.”
Edelman Smithfield is already a leading player in the financial communications industry. The firm’s asset management clients professionally manage more than $20 trillion combined, which, when coupled with insights from the annual Investor Trust survey, translates into a unique understanding of the global institutional investor landscape; Edelman Smithfield has advised on hundreds of transactions in the last five years, including some of the most prominent mergers and acquisitions, IPOs and restructurings.
Lex Suvanto, Global CEO of Edelman Smithfield, said, “We have a singular goal of building a financial communications powerhouse globally, and Edelman is providing the investment and runway to make this a reality. We are the only firm that specializes in the financial markets and strategic situations while bringing the reach and resources of broader Edelman. Together as a global team and with a unified banner and strategy, we will unlock new opportunities, while always prioritizing excellent client work, conducting ourselves with integrity and attracting and empowering an incredible team of dedicated advisors.”
Edelman Smithfield brings a strong leadership team with an impeccable track record of helping clients navigate the complex and dynamic financial markets. Global and regional leadership appointments include:
- Lex Suvanto, Global CEO
- John Kiely, Chairman of EMEA
- Andrew Wilde, Global Head of Financial Services
- Josh Hochberg, Global Chief Operating Officer
- Katie Spring, President, United States
- Alex Simmons, Head of EMEA
- Jason Leow, Head of APAC
Edelman Smithfield also includes leaders and teams in a total of 25 cities and 15 countries around the world.
In 2015, Edelman acquired Smithfield, a UK-based financial communications firm, as part of its ongoing investment and growth in financial communications. Since that time, the Edelman Smithfield brand has been rolled out in Germany, the Middle East and Canada. Edelman plans to commit significant resources to the continued expansion of the Edelman Smithfield platform in key markets around the world.
About Edelman
Edelman is a global communications firm that partners with businesses and organizations to evolve, promote and protect their brands and reputations. Our 6,000 people in more than 60 offices deliver communications strategies that give our clients the confidence to lead and act with certainty, earning the trust of their stakeholders. Our honors include the Cannes Lions Grand Prix for PR; Advertising Age’s 2019 A-List; the Holmes Report’s 2018 Global Digital Agency of the Year; and, five times, Glassdoor’s Best Places to Work. Since our founding in 1952, we have remained an independent, family-run business. Edelman owns specialty companies Edelman Data x Intelligence (research, data) and United Entertainment Group (entertainment, sports, lifestyle).
About Edelman Smithfield
Edelman Smithfield is a financial communications boutique that specializes in the financial markets and strategic situations with the full reach and resources of Edelman. The Edelman Smithfield team comprises approximately 250 advisors across more than 25 cities and 15 countries serving an expansive roster of top organizations around the world. www.EdelmanSmithfield.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005322/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom